

Contents Volume 21, 1987

Volume 21, Number 1

1987

CONTENTS

Special Issue: Adverse Events

- | | | |
|---|----|---|
| Allen Cato Robert Temple | 1 | Foreword and Acknowledgments |
| Allen Cato | 3 | Premarketing Adverse Drug Experiences: Data Management Procedures. Unexpected Death Occurring Early in Clinical Trials |
| Robert T. O'Neill | 9 | Statistical Analyses of Adverse Event Data from Clinical Trials. Special Emphasis on Serious Events |
| Karl E. Peace | 21 | Design, Monitoring, and Analysis Issues Relative to Adverse Events |
| Michael Weintraub Gerald Ginsberg | 29 | Evaluating Liver Enzyme Abnormalities in Clinical Trials Involving Diabetic Patients |
| Dorothy B. Windhorst Edward F. C. Pun Lonni A. Zubkoff | 39 | Data on Drugs and Adverse Experiences: Moving from the Specific to the General |
| Ursula Gundert-Remy | 47 | European View Toward Incorporating Adverse Events into Package Inserts |
| Joel Morganroth | 51 | Remote Data Entry and the Electronic New Drug Application: An Integrated Approach to Acquire, Analyze, and Review New Drug Data |
| Noel R. Mohberg | 55 | Some Observations on the Collection of Medical Event Data |
| Judith Kramer Littlejohn | 63 | Package Insert: View of a Rural Town Practitioner |

(Contents continued on next page)

A Primer on Postmarketing Surveillance

69 Editor's Note

71 Preface

HISTORICAL PERSPECTIVE

76 FDA Regulation of New Drugs

78 History of Postmarketing Surveillance in the United States

80 The Approach in Great Britain

83 Current Focus on Postmarketing Surveillance

83 Postmarketing Surveillance Activities of the FDA

83 Phase IV Studies

85 Summary of Industry Sponsored Phase IV Studies

EXECUTIVE BRIEF

93 Methods of Postmarketing Surveillance

95 Outline of Postmarketing Surveillance

99 Glossary of Postmarketing Surveillance Terms

BIBLIOGRAPHY

105 Pharmaco-Epidemiology Selected Bibliography

I Software Survey Section:

PATH/TOX SYSTEM

RLAB PC LIMS

BALANCE

MODEL 2600 CHROMATOGRAPHY DATA

ACQUISITION

CAPTURE!

SIPHAR: INTEGRATED COMPUTER SYSTEM

FOR PHARMACOKINETIC DATA ANALYSIS

SIGNWRITER (Instant Display Lettering)

PAPERBASE DELUXE

THE KEY

MEGASOURCE INVESTIGATIONAL DRUG

TRACKING SYSTEM

MKMODEL

Volume 21, Number 2

1987

CONTENTS

- Stuart L. Nightingale** 109 Regulatory Overview: Protection of Human Subjects—IRBs and Informed Consent
- Gurston Turner** 117 FDA's Conduct, Review, and Evaluation of Inspections of Clinical Investigators
Alan B. Lisook
Dana P. Delman
- Thomas J. Kirsch** 127 The Interrelationships of Sponsors, Clinical Investigators, and Institutional Review Boards
- Thomas H. Perez** 133 Adverse Drug Reaction Reporting: Comparison of Reports Received by a Specialized Registry and the Food and Drug Administration System
Joel N. Kuritsky
Gerald A. Faich
- Robert S. Stern** 137 Spontaneous Adverse Drug Reporting: Do Numbers Tell the Story?
- Raymond H. Farmen** 141 Management of Pharmacokinetic Data Using HP-3357/Mainframe IBM Interfacing
Judi F. Muniak
Kenneth A. Pittman
- Melvin P. Fisher** 153 Preparation and Maintenance of Prescription Drug Labeling
- Ann Summerfelt** 159 Implementation of Clinical Trials: Simple, but Not Easy
Frank R. Funderburk
- G. Edward Collins** 165 An Integrated Approach for Processing Information Inquiries at the Time of a New Product Launch
Cathy S. Frieden
Gilles Cloutier
Allen Cato
- Seymour Fisher** 173 Detecting Adverse Drug Reactions in Postmarketing Surveillance: Interview Validity
Stephen G. Bryant
Ronica M. Kluge
- Daniel E. Klingler** 185 A Drug Safety Evaluation On-Line Study Log
- Elizabeth H. Brown** 193 Standard Operating Procedures for Computer Systems Validation
- Leonard T. Sigell** 201 The Role of Drug Information Centers with Consumers
J. Frank Bonfiglio
Earl G. Siegel
Edwin A. McCray
Gaylene B. Tsipis

- Freya F. Hermann** 209 Analysis and Control of Costs Associated
Lee A. Wanke with Answering Drug Information Requests
- Paula Botstein** 217 Criteria for Approval of Controlled-Release
Products
- Sanford A. Miller** 221 Foods as Drugs
Frank Edward Scarbrough
- Ara Der Marderosian** 229 Overview of the Use of Food/Natural Products as
Drugs
- Norman R. Farnsworth** 245 International Perspectives Regarding the Use of
Food/Natural Products as Drugs
- I Software Survey Section
Sci-Mate Software System V2.0
Chromatography Software for
the HP-1000-A Series Computer
RЛАB II
2600 Chromatography Software for the
IBM PC and Compatibles

Volume 21, Number 3

1987

CONTENTS

- Gerald A. Faich** 251 Sources of Spontaneous Adverse Drug Reaction
Julie B. Milstien Reports Received by Pharmaceutical Manufacturers
Charles Anello
Carlene Baum
- Carlene Baum** 257 Differences in Manufacturer Reporting of
Gerald A. Faich Adverse Drug Reactions to the FDA in 1984
Charles Anello
Mary B. Forbes
- Stefan H. Unger** 267 Computer-Aided Drug Design in the Year 2000
- Robert A. Michalak** 277 Investigational Adverse Experience Reporting
- Daniel E. Klingler** 283 Documentation and Management of
Configurable Software

- C. A. Metz** 289 Development of a Training Program for
G. D. Gutknecht
J. C. Schneider
A. Q. Sheridan
C. J. Cross
- T. C. Vandermeulen**
K. P. Chapman
J. P. Keelan
W. Veldkamp
- Erika F. Nissman** 295 The Use of COSTART at Burroughs
Wellcome Company
- Fred Schneiweiss** 299 Adverse Reaction Thesauri Used in the
Pharmaceutical Industry
- Fiona M. Cunningham** 303 QA Report Auditing: A Procedure for Selecting and
Kevin J. Gough Identifying Data Points for Checking
- Nancy Mattison** 309 Postapproval Research Requested by the FDA at the
Barbara W. Richard Time of NCE Approval, 1970-1984
- Bart Holland** 331 Monitoring Adverse Drug Reactions Using a
Steven Marcus State Poison Control Center Data Base
- Alan M. Saltzman** 335 A MIS System for Worldwide Acquisition of Remote
Clinical Information
- G. James Davis** 353 The Successful Development Team: A Case Study
Daniel R. Klinger
- Theresa E. Stokes** 361 Clinical Data Management and Remote Data Entry
- Frederick H. Fern** 367 Dual Regulatory Pharmaceutical Labeling Schemes:
Lewis Bartell The Role of the Federal Preemption Doctrine
- I Software Survey Section:
CALS PEAKPRO
CALS LAB MANAGER

Volume 21, Number 4

1987

CONTENTS

- Craig E. Hammes** 377 Foreword and Acknowledgements
- William E. Gilbertson** 379 FDA OTC Drug Standards Versus Cosmetic
Standards

- Heinz J. Eiermann** 387 Regulatory Requirements for Marketing Cosmetics in the United States
- Paul M. Hyman** 393 Regulatory Risks of Marketing Drugs and Cosmetics
- C. L. Hagenbush** 403 Practical and Theoretical Distinctions Between Drugs and Cosmetics
- Ann H. Wion** 409 Legal Perspective—OTC Drugs and Cosmetics
- Elizabeth B. D'Angelo** 417 Foreword and Acknowledgements
- William J. Meddick** 419 Computer Systems Validation: Dollars and Sense
- Daniel E. Klingler** 431 The Role of Rapid Prototypes in Software Validation
- Daniel Shirley** 441 Software Validation Strategies for Clinical Trials Systems
- Graham Martin
J. Tony Wildsmith** 445 A New Approach to Error Reduction in the Acquisition and Delivery of Analytical Laboratory Data
- Thomas J. Ott
Stephen A. Herczeg
Robert K. Campbell** 455 Quality Assurance of Clinical Data in a Remote Data Entry Environment
- Will Anderson** 461 Software Validation Techniques
- D. C. Mattes
B. J. Clark** 471 Development of Systematic Data Access and Integrity Features for Pharmaceutical Computer Applications
- Jay Herson** 475 Validation of Database Management System Applications for Clinical Trials
- Jonathan S. Kahan** 481 Legal Implications of Software Validation
- Maryanne Malone** 487 Managing the Validation Process
- J. C. Lynch
M. A. Schreiber** 495 Documentation and Validation of a User Writer Program
- Michael Todd
Roger Landau
Theodore Koziol
Robert Dwyer
Kim Nitahara** 503 Validation of the Bioanalytical Computer Systems

517 Index to Volume 21, 1987

- I Software Survey Section:**
ILEUM ver. 2.0
CARDIOLAB
Compudex